Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago. These figures ...
Ovid Therapeutics Inc. (NASDAQ:OVID) is among the best US stocks under $10 to invest in. Analysts at Lucid Capital have begun coverage on Ovid Therapeutics Inc. (NASDAQ:OVID) with a Buy rating and a ...
The average one-year price target for Ovid Therapeutics (NasdaqCM:OVID) has been revised to $4.23 / share. This is an increase of 22.06% from the prior estimate of $3.47 dated September 27, 2025. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback